8-K: MetaVia Inc. Announces Year-End 2024 Financial Results and Provides Corporate Update

MetaVia Inc. reports its year-end 2024 financial results, highlighting progress in clinical development of its cardiometabolic assets, DA-1726 and DA-1241, and anticipates key data readouts and regulatory meetings in 2025.

Summary

• MetaVia Inc., a clinical-stage biotechnology company, announced its financial results for the year ended December 31, 2024.
• The company is focused on developing DA-1726 for obesity and DA-1241 for MASH.
• Top-line data from the MAD Part 2 of the Phase 1 trial of DA-1726 is expected in April 2025.
• Positive top-line 16-week results from the Phase 2a trial of DA-1241 for MASH were announced in December 2024.
• The company held an Advisory Committee meeting at the 9th Annual MASH-TAG 2025 Conference in January 2025 to discuss the DA-1241 results.
• R&D expenses for 2024 were approximately $21.6 million, compared to $9.2 million in 2023.
• General and administrative expenses were approximately $7.3 million for 2024, compared to $6.7 million in 2023.
• The net loss for 2024 was $27.6 million, or $3.56 per share, compared to a net loss of $12.5 million, or $2.46 per share, in 2023.
• Cash was $16.0 million as of December 31, 2024, and is expected to fund operations into the third quarter of 2025.
• The company anticipates an end-of-Phase 2 meeting with the FDA in the first half of 2025 for DA-1241.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the positive clinical trial results for DA-1241 and the anticipation of upcoming data for DA-1726; however, the increased net loss and decreased cash position temper the overall outlook.

Positives

• Positive top-line results from the Phase 2a trial of DA-1241 for MASH were reported, showing a reduction in ALT levels and lower HbA1C levels.
• DA-1241 demonstrated excellent tolerability with mostly mild adverse events and no drug-related serious adverse events.
• The company has $16.0 million in cash, expected to fund operations into the third quarter of 2025.
• MetaVia is adding additional cohorts to the DA-1726 study to further explore the maximum tolerated dose.

Negatives

• The net loss increased to $27.6 million in 2024 from $12.5 million in 2023.
• Cash decreased to $16.0 million as of December 31, 2024, from $22.4 million as of December 31, 2023.
• Other income decreased by $2.2 million due to a lower gain related to the change in fair value of warrant liabilities.

Risks

• The company's ability to execute its commercial strategy is subject to risks.
• The timeline for regulatory submissions and approvals is uncertain.
• The company's reliance on contract manufacturers and clinical study partners poses risks.
• Potential negative interactions between MetaVia's product candidates and other products could occur.
• The company's ability to initiate and complete clinical trials on a timely basis is subject to risks.
• Changes in applicable laws or regulations could have an impact.
• Changes to MetaVia's stock price could affect the terms of the license agreement and future fundraising.

Future Outlook

MetaVia anticipates top-line data from the DA-1726 Phase 1 trial in April 2025 and plans to commence an early proof-of-concept study in Q4 2025; the company also expects to present the full data set from the DA-1241 Phase 2a trial at a major medical meeting in 2025 and have an end-of-Phase 2 meeting with the FDA in the first half of 2025.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of MetaVia, stated that the company made exceptional progress advancing the clinical development of its two next-generation cardiometabolic assets throughout 2024.
• Mr. Kim expressed confidence that DA-1726 has the potential to become a best-in-class obesity drug, offering superior tolerability compared to currently marketed GLP-1 agonists.
• Mr. Kim stated that DA-1241's novel mechanism of action has the potential to result in a safe and effective treatment for MASH.

Industry Context

MetaVia is operating in the competitive cardiometabolic disease space, focusing on obesity and MASH, where there is a high unmet need for effective and well-tolerated treatments; the company's focus on dual-agonists and novel mechanisms of action positions it to potentially address limitations of existing therapies.

Comparison to Industry Standards

• The document mentions that many patients using current GLP-1 agonists discontinue treatment due to tolerability issues, with 20% to 30% stopping within the first two months and up to 70% discontinuing within a year.
• MetaVia aims to improve on these industry standards with DA-1726, which they believe will have superior tolerability compared to currently marketed GLP-1 agonists and those in late-stage clinical trials.
• The company is also exploring combination therapies for DA-1241, which has the potential to offer further benefits across the full spectrum of MASH, similar to strategies employed by companies like Intercept Pharmaceuticals and Madrigal Pharmaceuticals.

Stakeholder Impact

• Shareholders: The progress in clinical trials and financial results will impact shareholder value.
• Employees: The company's strategic realignment and focus on cardiometabolic diseases will affect employees.
• Patients: Successful development of DA-1726 and DA-1241 could provide new treatment options for obesity and MASH.

Next Steps

• Report top-line data from the MAD Part 2 of the Phase 1 trial of DA-1726 in April 2025.
• Present the full data set from the Phase 2a clinical trial of DA-1241 at a major medical meeting in 2025.
• Schedule an end-of-Phase 2 meeting with the FDA in the first half of 2025 for DA-1241.
• Commence the Phase 1 Part 3 trial for DA-1726 in the fourth quarter of 2025.

Key Dates

Keywords

MetaVia, DA-1726, DA-1241, MASH, Obesity, Clinical Trials, Financial Results, Cardiometabolic Diseases, Biotechnology, FDA